Highlights of This Issue 1307

SPECIAL FEATURES

CCR Translations

1309  Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies
Kim-Hien T. Dao and Jeffrey W. Tyner
See article, p. 1422

1312  New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
Riccardo Lencioni
See article, p. 1503

CCR Perspectives in Drug Approval

1315  Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?
Gilles Vassal, Birgit Geoerger, and Bruce Morland

Statistics in CCR

1326  Borrowing Information across Subgroups in Phase II Trials: Is It Useful?
Boris Freidlin and Edward L. Korn

CCR Drug Updates

1335  Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
Jean Hoffman-Censits and Wm. Kevin Kelly

Molecular Pathways

1340  Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity
Lisa A. Ridnour, Robert Y.S. Cheng, Christopher H. Switzer, Julie L. Heinecke, Stefan Ambs, Sharon Glynn, Howard A. Young, Giorgio Trinchieri, and David A. Wink

1347  Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver Cancer
Jessica Brownell and Stephen J. Polyak

HUMAN CANCER BIOLOGY

1353  Murine Microenvironment Metaproteomes Associate with Human Cancer Etiology and Intrinsic Subtypes
David H. Nguyen, Erik Fredlund, Wei Zhao, Charles M. Perou, Allan Balmain, Jian-Hua Mao, and Mary Helen Barcellos-Hoff

1363  PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
Kaoru Abiko, Masaki Mandai, Junzo Hamanishi, Yumiko Yoshioka, Norioi Matsumura, Tsukasa Baba, Ken Yamaguchi, Ryusuke Murakami, Ayaka Yamamoto, Budiman Kharma, Kenzo Kosaka, and Ikuo Konishi

1375  Rab25 Regulates Invasion and Metastasis in Head and Neck Cancer
Panomwat Amornphimoltham, Kamil Rechache, Jamie Thompson, Andrius Masedunas, Kantima Leelavahanichkul, Vyomesh Patel, Alfredo Molinolo, J. Silvio Gutkind, and Roberto Weigert

1389  MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer
San-Jian Yu, Jing-Ying Hu, Xia-Ying Kuang, Jian-Min Luo, Yi-Feng Hou, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Hou-Yan Song, and Zhi-Ming Shao

1400  HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification
Jianghua Zheng, Jinglong Wang, Xueqing Sun, Mingang Hao, Tao Ding, Dan Xiong, Xiumin Wang, Yu Zhu, Gang Xiao, Guansun Cheng, Meizhong Zhao, Jian Zhang, and Jianhua Wang

1411  Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer
<table>
<thead>
<tr>
<th>Cancer Therapy: Preclinical</th>
<th>Imaging, Diagnosis, Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1422</strong> Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia&lt;br&gt;Seiichiro Katagiri, Tetsuzo Tauchi, Seiichi Okabe, Yosuke Minami, Shinya Kimura, Taira Maekawa, Tomoki Naoe, and Kazuma Ohyashiki&lt;br&gt;See commentary, p. 1309</td>
<td><strong>1487</strong> 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors&lt;br&gt;Anish Thomas, Esther Mena, Karen Kurzdziel, David Venzon, Sean Khozin, Arlene W. Berman, Peter Choyke, Eva Szabo, Arun Rajan, and Giuseppe Giaccone</td>
</tr>
<tr>
<td><strong>1433</strong> Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition&lt;br&gt;Ying Zhang, Kaitlyn E. Farenholtz, Yanzhi Yang, Fadila Guessous, Charles G. diPierro, Valerie S. Calvert, Jianghong Deng, David Schiff, Wenjun Xin, Jae K. Lee, Benjamin Purrow, James Christensen, Emanuel Petricoin, and Roger Abounader</td>
<td><strong>1494</strong> Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma&lt;br&gt;Jelena Levi, Sri-Rajashekar Kothapalli, Sarah Bohndiek, Joon-Kee Yoon, Anca Dragulescu-Andrasi, Carsten Nielsen, Aleksandra Tisma, Sunil Bodapati, Gayatri Gowrishankar, Xinrui Yan, Carmel Chan, Daniela Starcevic, and Sanjiv Sam Gambhir</td>
</tr>
<tr>
<td><strong>1445</strong> Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-kB&lt;br&gt;Lorenz Bastian, Jana Hof, Madlen Pfau, Iduna Fichtner, Cornelia Eckert, Günter Henze, Javier Prada, Arend von Stackenberg, Karl Seeger, and Shabnam Shalapour</td>
<td><strong>1503</strong> Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization&lt;br&gt;Beom Kyung Kim, Seung Up Kim, Myeong-Jin Kim, Kyung Ah Kim, Do Young Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, and Chae Yoon Chon&lt;br&gt;See commentary, p. 1312</td>
</tr>
<tr>
<td><strong>1458</strong> Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide&lt;br&gt;Eric I. Zimmerman, Shuiying Hu, Justin L. Roberts, Alice A. Gibson, Shelley J. Orwick, Lie Li, Alex Sparreboom, and Sharyn D. Baker</td>
<td><strong>1512</strong> Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors&lt;br&gt;Anne F. Schott, Melissa D. Landis, Gabriela Dontu, Kent A. Griffith, Rachel M. Layman, Ian Krop, Lacey A. Paskett, Helen Wong, Lacey E. Dobrolecki, Michael T. Lewis, Amber M. Froehlich, Jaya Paranilam, Daniel F. Hayes, Max S. Wicha, and Jenny C. Chang</td>
</tr>
<tr>
<td><strong>1476</strong> Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells&lt;br&gt;Eric D. Mortenson, Saegwang Park, Zhujun Jiang, Shengdian Wang, and Yang-Xin Fu</td>
<td></td>
</tr>
</tbody>
</table>
1534 Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization
Ruben Niesvizky, Tomer M. Mark, Maureen Ward, David S. Jayabalun, Roger N. Pearse, Megan Manco, Jessica Stern, Paul J. Christos, Lena Mathews, Tsiporah B. Shore, Faiza Zafar, Karen Pekle, Zhaoxing Xiang, Scott Ely, Donna Skerret, Selina Chen-Kiang, Morton Coleman, and Maureen E. Lane

1547 Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer
Firas L. T. Al-Ubaidi, Niklas Schultz, Olga Loseva, Lars Egevad, Torvald Granfors, and Thomas Helleday

1557 Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, Eamala Vasudev, Michelle Knowles, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain, and Dan G. Duda

1567 Phase I Study of GRN1005 in Recurrent Malignant Glioma
Jan Drappatz, Andrew Brenner, Eric T. Wong, April Eichler, David Schiff, Morris D. Groves, Tom Mikkelsen, Steve Rosenfeld, John Sarantopoulos, Christina A. Meyers, Betty Lawrence, Mona Shing, Stephen Kelsey, Jean Paul Castaigne, and Patrick Y. Wen

1577 A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Hao Tang, Guanghua Xiao, Carmen Behrens, Joan Schiller, Jeffrey Allen, Chi-Wan Chow, Milind Suraokar, Alejandro Corvalan, Jianhua Mao, Michael A. White, Ignacio I. Wistuba, John D. Minna, and Yang Xie

Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Irinotecan or Paclitaxel in Early-Stage Breast Cancer
Christine E. Horak, Lajos Pusztai, Guan Xing, Ovidiu C. Trifan, Cristina Saura, Ling-Ming Tseng, Stephen Chan, Rosanne Welcher, and David Liu

Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients
Antonio Giordano, Brian L. Egleston, David Hajage, Joseph Bland, Gabriel N. Hortobagyi, James M. Reuben, Jean-Yves Pierga, Massimo Cristofanilli, and Francois-Clement Biddard

CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC
Rathi N. Pillai, Seth A. Brodie, Gabriel L. Sica, You Shaojin, Ge Li, Dana C. Nickleach, Liu Yuan, Vijay A. Varma, Dacian Bonta, James G. Herman, Malcolm V. Brock, Maria J.A. Ribeiro, Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri, and Johann C. Brandes

A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer

Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE
ABOUT THE COVER

The microphotograph shows the induction of apoptosis after combined treatment with bortezomib and the histone deacetylase inhibitor valproic acid in a xenograft mouse model of acute lymphoblastic leukemia (ALL). Human B-cell precursor ALL cells were injected subcutaneously into nonobese diabetic/severe combined immunodeficient mice. Tumor sections after treatments were stained with mAbs against human CD10 (red) indicating leukemia cells, cleaved caspase-3 (green) indicating apoptotic cells, and 4',6-diamidino-2-phenylindole (nuclei, blue). For details, please see the article by Bastian and colleagues on page 1445 of this issue.